CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its ...
CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a clinical-stage biotechnology company focused on the development of next-generation diagnostic tests for early detection of cancers, announced ...
IsoPSA Test Evaluates Prostate Cancer-Specific Structural Variants of the PSA Protein to Aid in the Diagnosis of High-Grade Prostate Cancer CLEVELAND, December 01, 2025--(BUSINESS WIRE)--Cleveland ...
Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, has opened a new, state-of-the-art facility. The ...
Cleveland Diagnostics said Monday it received Food and Drug Administration approval for a test that analyzes the structure of protein biomarkers in the blood for prostate cancer signals, to aid in ...
CGS Administrators, Inc., the Medicare Administrative Contractor with jurisdiction over Cleveland Diagnostics, issues final Local Coverage Decision (LCD) providing coverage of the IsoPSA prostate ...
Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, today announced an agreement designed to expand ...
About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, but the screening process for this relatively common cancer isn’t always straightforward. Diagnosis can be a drawn-out and ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that it has closed a Series D round ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results